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Abstract
Objective To document whether elements of a structured history and
examination predict adverse outcome of acute sore throat.
Design Prospective clinical cohort.
Setting Primary care.
Participants 14 610 adults with acute sore throat (≤2 weeks’ duration).
Main outcome measures Common suppurative complications (quinsy
or peritonsillar abscess, otitis media, sinusitis, impetigo or cellulitis) and
reconsultation with new or unresolving symptoms within one month.
ResultsComplications were assessed reliably (inter-rater κ=0.95). 1.3%
(177/13 445) of participants developed complications overall and 14.2%
(1889/13 288) reconsulted with new or unresolving symptoms.
Independent predictors of complications were severe tonsillar
inflammation (documented among 13.0% (1652/12 717); odds ratio 1.92,
95% confidence interval 1.28 to 2.89) and severe earache (5% (667/13
323); 3.02, 1.91 to 4.76), but the model including both variables had
modest prognostic utility (bootstrapped area under the receiver operator
curve 0.61, 0.57 to 0.65), and 70% of complications (124/177) occurred
when neither was present. Clinical prediction rules for bacterial infection
(Centor criteria and FeverPAIN) also predicted complications, but
predictive values were also poor and most complications occurred with
low scores (67% (118/175) scoring ≤2 for Centor; 126/173 (73%) scoring
≤2 for FeverPAIN). Previous medical problems, sex, temperature, and
muscle aches were independently but weakly associated with
reconsultation with new or unresolving symptoms.
Conclusion Important suppurative complications after an episode of
acute sore throat in primary care are uncommon. History and examination
and scores to predict bacterial infection cannot usefully identify those
who will develop complications. Clinicians will need to rely on strategies
such as safety netting or delayed prescription in managing the uncertainty
and low risk of complications.
Introduction
Respiratory tract infections are the commonest acute illnesses
managed in everyday practice, and most patients receive
antibiotics,1 whether for a lower respiratory tract infection or
acute sore throat. Prescribing of antibiotics in the community
is a key driver of antibiotic resistance, which may lead to many
untreatable serious infections,2 3 and since new classes of
antibiotics are not being developed, the key to maintaining the
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precious resource of antibiotics is to reduce antibiotic use for
those who will receive no meaningful clinical benefit.
Although systematic reviews and randomised trials of antibiotics
in acute sore throat have shown a modest effect on symptoms,
prescribing antibiotics prevents both suppurative complications
(quinsy, otitis media, sinusitis, cellulitis) and non-suppurative
complications, although non-suppurative complications are
probably currently rare in resource rich settings.4-6 Thus it is
important not to deny those patients at major risk of severe
illness or complications the benefit from antibiotics. Both
patients and general practitioners are concerned about the danger
of severe illness from upper respiratory tract infections, and in
the absence of evidence general practitioners currently use a
range of ad hoc clinical criteria to justify prescribing antibiotics.7
A better understanding of those patients who are or are not at
risk of poorer outcomes could help tackle such concerns.7
A key question is therefore how to better target antibiotics.
Management of sore throat has traditionally been advocated
based on the risk of infection with group A β haemolytic
streptococci,8-10 including the simple Centor criteria—three out
of four of pus, cervical nodes, a history of fever and no history
of cough—which are widely advocated in guidance.11-15
However, these criteria have low specificity12 for bacterial
infection, leading to high antibiotic use.12 Furthermore, small
studies in typical primary care settings have suggested other
features might be useful in refining the criteria, such as short
previous duration and pain severity.10 16We previously reported
evidence that group C and G streptococci present in a similar
manner to group A streptococci,17 and in combination with
another diagnostic cohort we proposed a five item score,
FeverPAIN (Fever, Pus, rapid Attendance (illness ≤3 days),
severe Inflammation, and No cough or coryza). However, it is
unclear whether those who are more likely to have streptococcal
infection are also more likely to have worse symptoms,
prolonged illness, or complications. To our knowledge only one
case-control study has used routine data on the suppurative
complications of acute sore throat, which showed a higher risk
for middle aged men who smoke,18 but no prospective clinical
study has addressed whether elements of standard history and
examination can usefully predict complications.
We assessed the clinical predictors of complications after
presentation of acute sore throat, and investigated whether
clinical prediction scores for bacterial infection predict common




The concept of the study was to develop a simple one page paper
or web based clinical proforma documenting clinical features
to facilitate the generation of a large prospective cohort to
predict adverse outcomes, among patients recruited
consecutively where time for consent in busy winter clinics
allowed. Within the observational study, we nested smaller
studies to develop and trial a clinical scoring method for
bacterial infection. All the studies used the same baseline clinical
proforma and the same outcomes measures. The nested studies
concerned two consecutive diagnostic cohorts (n=1107) where
a clinical score to predict bacterial infection was developed, and
a randomised trial (n=1781) that compared the use of the clinical
score and the targeted use of a rapid antigen detection test with
delayed antibiotic prescribing (see supplementary appendix 1
for details).
Practitioner inclusion criteria—So that the impact of antibiotics
could be potentially explored we recruited general practitioners
who reported prescribing immediate antibiotics in 50% or less
of patients with tonsillitis. General practitioners had the option
of using either paper or web based clinical proformas. Initial
recruitment was among six local networks (Southampton,
Bristol, Birmingham, Oxford, Cardiff, and Exeter) but was
extended nationally during the last 18 months of recruitment.
Patient inclusion criteria—We included previously well patients
aged 16 or more with acute uncomplicated illness (≤14 days),
who presented with sore throat as the main symptom and had
an abnormal examination result of the pharynx (identical criteria
to our previous studies19). Exclusion criteria were severe mental
health problems (for example, cognitive impairment associated
with being unable to consent or assess history) and complicated
illness (for example, complication at presentation or incipient
complication; immune suppression).
Baseline clinical proforma—This consisted of a single clinical
sheet documenting age, sex, current smoking status, previous
duration of illness, and the presence and severity of baseline
symptoms (sore throat, difficulty swallowing, fever during the
illness, runny nose, cough, feeling unwell, diarrhoea, vomiting,
abdominal pain, headache, muscle aches, sleep disturbance,
earache). Symptoms were recorded using 4 point Likert scales
(none, a slight problem, a moderately bad problem, a severe
problem), and the presence of signs (pus, nodes, cervical nodes,
temperature, fetor, palatal oedema, difficulty speaking due to
sore throat) to include those used in previous clinical
scores.5 10 20 21
Documentation of outcomes
We defined suppurative complications (the primary outcome)
as a new diagnosis recorded in the clinical record in the month
after the index presentation of otitis media, sinusitis, quinsy,
cellulitis (the major complications based on previous systematic
review and trial evidence4-6), assessed using a standardised
proforma by staff in general practices or by primary care
research network staff. The structured proforma was developed
iteratively following initial attempts at proformas that were
difficult to operationalise reliably. No formal training was
provided: the proformas were designed to be used with minimal
training across a wide geographical area, and came with a
manual of instructions, supported by study staff at the main
centre if there were queries.
Where information about complications was not available from
notes reviewwe used information from a freepost card returned
directly to the study centre by patients. To minimise subjective
judgments by the reviewing staff we separated the notes review
proforma into a wide variety of terms reflecting the possible
consultation diagnosis or symptom presentation.We documented
inter-rater reliability of the assessment of complications and
progression of illness by second raters blind to the first rating
among 153 patients. The patients for this reliability study were
selected from two of the sites, in urban practices close to each
study centre, chosen for ease of access to the study centres.
Progression/non-resolution of illness (secondary
outcome)—This was defined as reconsultation with unresolving
symptoms or development of a new respiratory diagnosis,
symptom, or sign within a month of the index
presentation—similar to outcomes used previously in a cohort
of children22 and in a large trial of antibiotics for lower
respiratory tract infection in adults.23
Selection bias—We asked general practitioners or nurses to
document when eligible patients were not entered into the study,
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2013;347:f6867 doi: 10.1136/bmj.f6867 (Published 25 November 2013) Page 2 of 14
RESEARCH
the reason why, treatment, and clinical characteristics, but
completion of this information was poor, since the reasons
patients were not recruited (time pressures at the busiest times
of year) made it difficult to document additional information.
Sample size—For the sample size calculations we assumed 5%
two sided significance and 80%power, using theNQuery sample
size program (Statistical Solutions).We assumed that a clinically
useful variable would be likely to predict complications with
an odds ratio of at least 2.5, that important predictive variables
would have a prevalence among those with complications of
35-75%,5 6 24 and that complications (quinsy, otitis media,
cellulitis, sinusitis) occur 1:150 times among unselected
patients.24 On the assumption that the group not receiving
immediate antibiotics might be the most appropriate group in
which to develop a model, we determined that 6749 data forms
would be needed among that group. Our previous data suggested
minimal clustering by general practitioner but, assuming an
intracluster correlation coefficient of 0.01, we estimated that
we might need to recruit up to 17 412 patients to allow both for
up to 50% of patients receiving immediate antibiotics and for
clustering.
Statistical analysis
We assessed the individual predictors of complications or
non-resolution or progression of symptoms using logistic
regression for binary outcomes. The multivariate models
controlled for the potential confounding effect of antibiotic
prescribing, clustering by practice, and other significant
individual predictors. The analysis was undertaken on the
complete dataset, without imputing missing data. We used
backward selection and retained variables in the final model
only if they were significant predictors at the 5% level. The
primary analysis used variables that had been found to be
predictive of bacterial infection in previous cohorts and the
nested diagnostic study (fever, absence of cough, absence of
coryza, difficulty swallowing, previous duration, muscle aches,
headache, temperature, and purulence), but following peer
review a secondary analysis included the full range of
variables—diarrhoea, vomiting, abdominal pain, earache,
generally unwell, fetor, and palatal oedema. We developed a
clinical score based on a simple sum of the variables that
independently predicted complications in multivariate analysis.
We documented the sensitivity, specificity, and positive and
negative predictive values of the score for predicting
complications. To overcome the problem of over-fitting of a
score derived from the same cohort as the component variables,
we used bootstrapped estimates of the area under the receiver
operator curve to document the overall prognostic value of each
predictive variables and the score.25 We also assessed whether
clinical scores previously developed to predict bacterial
infections also predicted complications. The clinical scores we
used were a modified version of the Centor criteria, which were
developed to predict the presence of group A streptococci (fever
during the previous 24 hours, purulent tonsils, the absence of
cough, and cervical nodes), and a score developed to predict
the presence of Lancefield groups A, C, and G streptococci
(FeverPAIN: Fever, Purulent tonsils, rapid Attendance (illness
≤3 days), severely Inflamed tonsils, and No cough or coryza).
We also assessed a modified version of the FeverPAIN score
but excluding previous rapid attendance (owing to concerns
about the generalisability to other clinical settings of the variable
“rapid attendance”).
We agreed the final analysis plan based on a review of the
characteristics of patients in the cohort who did and did not
receive antibiotics: given the important differences between
such patients, we judged that developing a model among those
who were not prescribed antibiotics (our original plan) would
be unrepresentative of the key patient groups, so we revised our
primary analysis to include the whole cohort. Antibiotic
prescribing would only be expected to partially attenuate the
observed risk of complications,18 hence multivariate analyses
controlled for both antibiotic prescribing strategy and clustering
by recruiting clinician. We performed a secondary analysis
among those who were not prescribed antibiotics and checked
for interactions with prescribing strategy—that is, we assessed
a differential estimate for predictors according to prescribing
strategy.
Results
Overall, 14 610 adolescents and adults were recruited between
10 November 2006 and 1 June 2009 from 616 practices
(figure⇓). Table 1⇓ shows the clinical characteristics of the
participants. The inter-rater reliability for assessing
complications was good (κ=0.95; of 11 patients with
complications only one was judged not to have a complication
on the second assessment), as was return with non-resolution
of symptoms (κ=0.84; of 29 patients documented as reconsulting
with new or worsening symptoms only one required
modification of the result on the second assessment). Few
variables had lots of missing data (see supplementary appendix
4).
Complications
The major suppurative complications of acute sore throat
(quinsy, otitis media, sinusitis, impetigo or cellulitis) occurred
in approximately 1% of patients regardless of whether they were
given antibiotics, not given antibiotics, or given delayed
antibiotics (table1). We recruited 7161 patients who did not
receive immediate antibiotics (more than we required based on
our minimal sample size calculation), but clinical differences
were noticeable between those not prescribed antibiotics, those
prescribed antibiotics immediately, and those given delayed
antibiotics (for example, purulence, fever, tonsillar
inflammation, table 1).
In multivariate analysis, predictors of complications were severe
tonsillar inflammation (documented among 13.0% (1652/12
717); odds ratio 1.92, 95% confidence interval 1.28 to 2.89)
and severe earache (documented among 5.0% (667/13 323),
3.02, 1.91 to 4.76) (table 2⇓). However, the model with both
variables hadmodest prognostic utility (bootstrapped area under
the receiver operator curve 0.61, 0.57 to 0.65), and 70% of
complications (124/177) occurred where neither was present.
The bootstrapped area under the receiver operator curve for a
simple clinical score generated using the sum of these two
variables (a score taking the value 0, 1, or 2) was little different
(0.61, 0.57 to 0.65, table 3⇓). The predictive value of severe
earache was not likely to be simply an incorrect initial diagnosis
(that is, missed diagnosis of otitis media) because severe earache
significantly predicted all complications, including quinsy and
otitis media (otitis media 5.27, 2.91 to 9.51; P<0.001; quinsy
3.04, 1.35, 6.84; P=0.007; sinusitis 1.73, 0.54 to 5.54; P=0.354,
cellulitis or impetigo 1.40, 0.19 to 10.55; P=0.742).
Supplementary appendix 3 shows the predictive values of
individual variables. The sensitivity of a Centor score of 4 or
more for complications was 17/175 (9.7%), and the positive
predictive value was 1.7% (17/995). For FeverPAIN, a score
of 4 or more also had a low sensitivity (12.7%: 22/173) and
positive predictive value (2.1%: 22/1064). Most complications
occurred with low scores, with 67% (118/175) scoring 2 or less
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for the Centor criteria and 73% (126/173) scoring 2 or less for
FeverPAIN (table 4⇓).
Secondary analysis of complications in no
antibiotic prescription group
There was no evidence that either severe tonsillar inflammation
or severe earache predicted outcome significantly differently
for the different antibiotic prescribing strategies (likelihood
ratio test for interaction terms P=0.753 and P=0.304,
respectively). Selecting just the no antibiotic group, severe
tonsillar inflammation similarly predicted the development of
complications but with wide confidence intervals owing to the
few complications and lower power (odds ratio 1.63, 95%
confidence interval 0.37 to 7.22; P=0.52), and severe earache
also predicted complications (3.11, 1.47 to 6.58; P<0.01). We
also found similar predictive values for both Centor and
FeverPAIN score in the no antibiotic group.
Reconsultations with unresolving or new
symptoms
In multivariate analysis, reconsultations with unresolving or
new symptoms was predicted by sex, number of medical
problems, age, a history of fever, temperature, and muscle aches
(table 5⇓ and supplementary appendix 2). Predictive values
were, however, mostly weak (odds ratios <1.5) and the
bootstrapped area under the receiver operator curve for the
model using the exact coefficients was modest (0.58, 95%
confidence interval 0.57 to 0.60), so it was not possible to
develop a useful clinical prediction rule. A modified Centor
score of 4 or more or modified FeverPAIN score (when
excluding previous rapid attendance) predicted new or
unresolving symptoms only at high scores, again with modest
odds ratios (table 6⇓). The clinical score developed to predict
complications again had low prognostic utility for
reconsultations (bootstrapped area under the receiver operator
curve 0.55, 95% confidence interval 0.53 to 0.57) (table 7⇓).
Discussion
Severe earache and tonsillar inflammation in acute sore throat
predict the development of complications, but most cases of
complications of acute sore throat occur in the absence of either
variable, so history taking and examination in primary care are
of limited predictive value. The scores used to assess risk of
bacterial infection are also not useful in predicting
complications. The most important suppurative complications
are uncommon in a resource rich setting.
Strengths and weaknesses of this study
The study was designed for rapid recruitment to minimise
selection bias using a simple clinical proforma to generate a
large generalisable prospective cohort. Although a few practices
also recruited patients for more intensive substudies (two
diagnostic studies and a randomised trial), patients could be
recruited to the current study if they declined those studies, so
there were minimal barriers to recruitment. We adjusted for
antibiotic prescribing in the analysis, and most of the variables
predicting antibiotic prescriptions did not predict complications,
Nevertheless, we may not have accurately controlled for the
impact of antibiotics, since compliance in routine settings can
be poor,26 and although evidence of confounding by indication
was minimal (estimates changed little when controlling for
antibiotic prescribing), residual confounding by indication may
have attenuated predictive values. Similarly, the use of steroids
and non-steroidal anti-inflammatory drugs may be relevant to
outcome, but steroids were not used in this dataset and since
most use of non-steroidal anti-inflammatory drugs is from over
the counter purchases rather than as prescribed drugs, the impact
of non-steroidal anti-inflammatory drugs cannot be estimated.
The type of antibiotic might have modified the outcome, but
the study had limited power to assess this since most of the
prescriptions were for phenoxymethylpenicillin. We recruited
fewer patients than we originally anticipated owing to funding
limitations, and so type 2 error is possible. As it transpired, we
recruited more patients not receiving immediate antibiotics than
theminimumwe initially anticipated. Furthermore, the inclusion
of participants prescribed antibiotics in the primary analysis
provided considerably more power. Patients were recruited at
the busiest times of year, and as with other studies of acute
infection,23 27 documentation of the details of those not
approached was poor owing to time pressures (since time
pressure to recruit also meant time pressure to document
non-recruitment). Although the diagnosis of quinsy and cellulitis
is relatively straightforward, the clinical diagnosis of otitis media
(www.sign.ac.uk/guidelines/fulltext/66) or sinusitis (www.cks.
nhs.uk/sinusitis) is likely to be more variable, which will have
reduced the power to find associations. However, the systematic
review of trials4 reviewed clinical diagnoses made in medical
records so the data in the current study was comparable, if not
preferable, because we used a highly structured record review
proforma that was reliable for both complications and
progression of symptoms. Outcome was assessed in routine
clinical records, and although the original clinical reports forms
were not available, since these were clinical records, baseline
criteria will have also been (variably) recorded in the notes, and
so some bias was possible. However, neither clinicians nor those
who reviewed the notes (mostly not the clinicians who had
recruited patients) had any basis for knowing what variables
might predict complications. The most plausible bias would be
that those clinicians who were familiar with the individual
Centor criteria might be more likely to record complications
where individual features of the Centor criteria were present.
However, since none of the features of the Centor criteria were
found to predict complications, even this tenuous series of links
seem implausible. The fact that at least two variables predicted
complications (tonsillar inflammation, earache), there was a
progressive increase in the odds ratios for FeverPAIN, and the
impact of antibiotic strategies in line with the trial evidence
suggests outcome ascertainment was probably adequate. Using
notes review for the broader definition of return to the surgery
with unresolving or new symptoms—which is a much more
inclusive outcome, and shown to be a useful outcome in a
previous large international trial23—demonstrated even less
predictive value for key variables, with lower odds ratios. Errors
in exposure ascertainment will also have occurred: however,
the study used the kind of clinical assessment of symptoms and
signs used in everyday practice, which has proved successful
in identifying predictors of bacterial infection,17 and since this
was designed as a pragmatic study to assess the value of routine
clinical history taking and examination, the results reflect more
faithfully the utility of predictor variables in routine care. The
complication rate in the current study was also of a similar
magnitude to that of the trial data4 and to other previous studies
in routine practice (for example, complication rate 1:400 for
quinsy, and 0.8% including other suppurative complications in
a previous UK pragmatic trial,19 24 1:1000 for quinsy in routine
observational studies1), which supports the likely generalisability
of the results, as does the wide range of general practitioners
and practices involved. In the United Kingdom, rapid antigen
detection tests are rarely used, so it is possible that such tests
might predict complications, but since the bacterial scores were
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not predictive, and since rapid antigen detection tests do not
detect group C and G streptococci, it is unclear whether these
tests would be useful in predicting complications.
Main results in context of other literature
Complications were uncommon: no non-suppurative
complications occurred, and less than 2% of patients developed
complications overall. Only severe tonsillar inflammation and
severe earache (among 13.0% and 5.0% of the cohort,
respectively) significantly predicted the development of
complications in both univariate and multivariate analysis, but
the predictive value was limited. Severe earache predicted
complications but did not significantly predict bacterial
infections in the previous nested diagnostic studies. The finding
that severe earache is a predictor is not simply due to
misdiagnosis at presentation, because severe earache also
predicted complications other than otitis media. One possibility
is that severe earache may be an indicator of severe pharyngeal
inflammation around the opening to the eustachean tubes or
inflammation of the eustachean tubes, with referred ear pain.
This explanation would be consistent with the finding that severe
tonsillar inflammation is predictive, and raises the possibility
that inflammatory markers such as C reactive protein might be
helpful. Previous clinical scores designed to predict bacterial
infection (Centor criteria, FeverPAIN) also predicted
complications but only at high scores and again with low
sensitivity and positive predictive values. To date, validation
of the Centor score in clinical datasets has concentrated on
predicting the presence of groupA streptococci, and not assessed
the prediction of clinical outcomes such as complications.28 A
previous study of routine data from practice documented that
middle aged men who smoke were most likely to develop
complications,18 which we could not confirm in the current
study. The number of previous medical problems, sex,
temperature, muscle aches, and previous bacterial scores weakly
predicted reconsultation with new or non-resolving symptoms.
In the absence of good clinical prediction of complications,
clinicians and patients are therefore left in some uncertainty.
Patients are not, however, just concerned about complications
but also about poorly controlled symptoms, and even though
the FeverPAIN score did not usefully predict complications,
using this score can help both in the management of symptoms
and the reduction in antibiotic use compared with an empirical
delayed prescription strategy.29 Furthermore, clinicians can
reassure their patients that clinically important complications
are uncommon and that many complications are uncomfortable
but self limiting (sinusitis, otitis media) and in most cases can
be treated with analgesics.11 Those that are mostly not self
limiting (cellulitis, quinsy) can be treated either with antibiotics
(cellulitis) in an outpatient setting or, in the case of quinsy, with
a short hospital admission. Attempts to avoid complications by
liberal prescribing for a broad group of patients has been
modelled by the National Institute for Health and Care
Excellence and shown clearly not to be cost effective,11 and
complications were of a similar order of magnitude among the
patients who were and were not prescribed antibiotics.
Uncertainty in clinical practice in primary care is an everyday
reality and can be managed in this case either by sensible safety
netting, including clear advice to patients about what to look
for (particularly continuing fever, progressive difficulty
swallowing, or the appearance of spreading erythema in the
skin), the expected time course, and actions to be taken.30
Alternatively, the delayed prescription strategy could be used
(where antibiotics are advised only if progression or
non-resolution of symptoms is significant).11 The group most
likely to benefit from either immediate or delayed antibiotic
prescription in preventing complications are the small number
with both severe tonsillar inflammation and severe earache (1%
of the cohort), 1 in 20 of whom will develop complications.
Clinical implications
The most important suppurative complications of acute sore
throat in primary care are uncommon, and history and
examination are not useful in facilitating the prediction of
complications or of reconsultations. Since a policy of liberal
antibiotic prescription for sore throat to prevent complications
is highly unlikely to be cost effective, and clinicians cannot rely
on clinical targeting to predict most complications, clinicians
will need to rely on strategies such as safety netting or delayed
prescription in managing the low risk of suppurative
complications.
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What is already known on this topic
Antibiotic prescription rates are rising again and have exceeded the peak in the late 1990s
General practitioners currently use several clinical criteria to justify prescribing to prevent complications in the absence of evidence
The only case-control study to date showed a higher risk for middle aged men who smoke
What this study adds
The most important suppurative complications of acute sore throat in primary care are uncommon
These complications cannot usefully be predicted by either history and examination findings, or the previously developed scores for
bacterial infection
Clinicians cannot rely on their own ad hoc clinical criteria to justify antibiotic prescribing to prevent complications and will need to rely
on strategies such as safety netting or delayed prescription
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Tables
Table 1| Characteristic of patients at index consultation. Values are numbers (percentages) unless stated otherwise
Delayed antibioticsGiven antibioticsNot given antibioticsCharacteristics
Clinical assessment:
3.06 (0.7)3.32 (0.6)2.93 (0.7)Mean (SD) severity of sore throat/difficulty swallowing (4 point Likert scale)
4.3 (3.3)4.6 (4.1)5.0 (6.5)Mean (SD) previous duration in days
34.1 (14.6)32.7 (14.2)34.7 (15.4)Mean (SD) age (years)
1770/2501 (70.8)4147/6269 (66.2)3610/5243 (68.9)Women
481/2484 (19.4)1445/6240 (23.2)1016/5212 (19.5)Smoker
1268/2317 (54.7)4109/5704 (72.0)2279/4852 (47.0)Fever in past 24 hours
36.8 (0.6)37.0 (0.8)36.7 (0.6)Mean (SD) temperature (°C)
654/2495 (26.2)3751/6232 (60.2)376/5213 (7.2)Pus on tonsils
178/2344 (7.6)1418/5855 (24.282)86/4923 (1.8)Severely inflamed tonsils
0.2 (0.4)0.2 (0.5)0.2 (0.5)Mean (SD) No of previous medical problems
222/2382 (9.5)864/5932 (14.6)803/4974 (16.1)Return <4 weeks with new or worsening symptoms
21/2382 (0.9)78/5932 (1.3)75/4974 (1.5)Return <4 weeks with complications
Individual complications:
6/2382 (0.3)30/5932 (0.5)11/4974 (0.2)Quinsy
3/2382 (0.1)12/5932 (0.2)23/4974 (0.5)Sinusitis
11/2382 (0.5)27/5932 (0.5)31/4974 (0.6)Otitis media
1/2382 (0.0)9/5932 (0.2)10/4974 (0.2)Celluliltis or impetigo
Denominators vary due to missing data.
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No (%) with no
complicationsVariables
Predictors:
0.680.94 (0.70 to 1.26)0.821.04 (0.77 to 1.39)89/177 (50.3)6503/13 164 (49.4)Previous duration ≤3
days
0.131.33 (0.92 to 1.92)0.041.40 (1.02 to 1.93)119/173 (67.2)7825/13 182 (59.4)Fever (during past 24
hours)
0.181.26 (0.90 to 1.77)0.141.26 (0.93 to 1.72)117/177 (66.1)7938/ 13 175 (60.3)Muscle aches
0.721.06 (0.78 to 1.44)0.441.13 (0.83 to 1.56)120/177 (67.8)8560/13 173 (65.0)Headache
0.760.95 (0.67 to 1.34)0.371.15 (0.85 to 1.57)73/167 (43.7)4962/12 325 (40.3)Sore throat†
0.621.09 (0.79 to 1.50)0.591.08 (0.81 to 1.46)81/177 (45.8)5770/13 187 (43.8)Absence of cough
0.700.94 (0.70 to 1.27)0.700.94 (0.70 to 1.28)99/173 (57.2)7493/12 771 (58.7)Absence of runny nose
0.750.95 (0.72 to 1.27)0.880.98 (0.72 to 1.32)83/173 (48.00)6200/12 767 (48.6)Absence of cough and
runny nose
0.411.21 (0.77 to 1.89)0.121.36 (0.92 to 2.01)31/177 (17.5)1780/13 188 (13.5)Generally unwell†
0.560.83 (0.44 to 1.56)0.390.77 (0.43 to 1.39)12/177 (6.8)1087/13 179 (8.3)Diarrhoea
0.171.32 (0.89 to 1.95)0.031.43 (1.03 to 1.97)55/177 (31.6)3246/13 177 (24.6)Disturbed sleep†
0.890.98 (0.69 to 1.37)0.261.20 (0.88 to 1.64)64/167 (38.3)4204/12 323 (34.1)Difficulty swallowing†
<0.013.02 (1.91. to 4.76)<0.013.22 (2.10 to 4.96)25/177 (14.2)642/13 163 (4.9)Earache†
0.980.98 (0.13 to 7.10)0.951.07 (0.15 to 7.73)1/177 (0.6)70/13 146 (0.5)Vomiting†
0.231.90 (0.67 to 5.41)0.142.13 (0.78 to 5.82)4/177 (2.3)142/13 149 (1.1)Abdominal pain†
Examination:
0.411.18 (0.79 to 1.75)0.4231.17 (0.79 to 1.74)31/174 (17.8)1981/12 704 (15.6)Temperature >37.5°C
0.490.86 (0.57 to 1.31)0.940.99 (0.72 to 1.35)60/177 (33.9)4495/13 162 (34.2)Purulent tonsils
0.351.20 (0.82 to 1.76)0.481.13 (0.80 to 1.63)131/171 (76.6)9320/12 560 (74.2)Cervical glands
0.130.78 (0.56 to 1.08)0.140.79 (0.58 to 1.08)63/175 (36.0)5460/13 119 (41.6)Tender cervical glands
<0.011.92 (1.28 to 2.89)<0.011.84 (1.28 to 2.66)37/173 (21.4)1615/12 544 (12.9)Severely inflamed tonsils
0.900.97 (0.62 to 1.51)0.831.05 (0.69 to 1.58)27/176 (15.3)1930/13 081 (14.8)Fetor
0.851.04 (0.69 to 1.57)0.671.08 (0.77 to 1.52)45/176 (25.6)3168/13 106 (24.2)Palatal oedema
*Controlling for clustering, antibiotic prescribing, and other independently predictive covariates (severely inflamed tonsils and very bad earache).
†Defined as very bad.
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Table 3| Predictive value of clinical score using severely inflamed tonsils and earache
P value
Multivariate odds ratio* (95%
CI)P value
Univariate odds ratio (95%
CI)
No (%) with complications
(n=177)
No (%) with no complications
(n=13 187)Clinical score
—1.00—1.00124 (70.1)11 093 (84.1)0
<0.012.41 (1.62 to 3.58)<0.012.12 (1.51 to 2.99)45 (25.4)1954 (14.8)1
<0.015.44 (2.51 to 11.79)<0.015.15 (2.47 to 10.74)8 (4.5)140 (1.1)2
*Controlling for clustering and antibiotic prescribing.
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Table 4| Predictive value of bacterial clinical scoring methods for complications
P value
Multivariate odds ratio* (95%
CI)P valueUnivariate odds ratio (95%CI)
No (%) with
complications




0.141.33 (0.91 to 1.96)0.761.06 (0.74 to 1.53)61 (34.9)4408 (34.3)2
0.151.39 (0.88 to 2.19)0.940.98 (0.65 to 1.48)40 (22.9)3113 (24.2)3
0.021.94 (1.13 to 3.35)0.311.33 (0.77 to 2.30)17 (9.7)978 (7.6)4
n=173n=12 363FeverPAIN:
—1.00—1.0084 (48.6)6391 (51.7)0/1
0.251.26 (0.85 to 1.86)0.931.02 (0.70 to 1.48)42 (24.3)3139 (25.4)2
0.231.36 (0.82 to 2.23)0.791.06 (0.68 to 1.66)25 (14.5)1791 (14.5)3
0.012.09 (1.18 to 3.70)0.051.61 (1.00 to 2.58)22 (12.7)1042 (8.4)4/5
n=173n=12 398FeverP(A)IN†:
—1.00—1.00111 (64.2)8592 (69.3)0/1
0.111.40 (0.92 to 2.12)0.611.11 (0.75 to 1.63)34 (19.7)2381 (19.2)2
0.021.87 (1.10 to 3.16)0.171.40 (0.87 to 2.26)20 (11.6)1105 (8.9)3
0.012.57 (1.22 to 5.43)0.081.94 (0.94 to 4.00)8 (4.6)320 (2.6)4
*Controlling for clustering and antibiotic prescribing.
†Not including attendance.
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No (%) with new or
unresolving symptoms
No (%) with no new or
unresolving symptomsVariables
Predictors:
0.900.99 (0.88 to 1.12)0.560.97 (0.88 to 1.07)927/1900 (48.8)5665/11 441 (49.5)Previous duration ≤3
days
0.341.09 (0.92 to 1.29)0.021.13 (1.02 to 1.25)762/1780 (42.8)4273/10 712 (39.9)Sore throat†
<0.011.21 (1.08 to 1.36)<0.011.21 (1.09 to 1.33)1199/1894 (63.3)6745/11 465 (58.8)Fever (during past 24
hours)
0.031.14 (1.02 to 1.27)<0.011.19 (1.08 to 1.32)1207/1893 (64.1)6848/11 459 (59.9)Muscle aches
0.941.00 (0.89 to 1.14)0.241.06 (0.96 to 1.18)1254/1894 (66.2)7426/11 456 (64.8)Headache
0.250.93 (0.82 to 1.05)0.040.90 (0.82 to 0.99)788/1895 (41.6)5063/11 104 (44.2)Absence of cough
0.790.98 (0.85 to 1.13)0.330.95 (0.86 to 1.05)1060/1840 (57.6)6532/11 104 (58.8)Absence of runny nose
0.630.97 (0.84 to 1.11)0.110.92 (0.84 to 1.02)862/1840 (46.9)5421/11 100 (48.8)Absence of cough and
runny nose
0.161.13 (0.95 to 1.33)0.011.20 (1.05 to 1.38)293/1895 (15.5)1518/11 470 (13.2)Generally unwell†
0.461.08 (0.89 to 1.30)0.181.12 (0.95 to 1.34)171/1893 (9.0)928/11 463 (8.1)Diarrhoea
0.231.10 (0.94 to 1.30)0.011.16 (1.04 to 1.30)499/1837 (27.2)2700/11 097 (24.3)Disturbed sleep†
0.491.06 (0.89 to 1.26)0.261.06 (0.96 to 1.18)630/1782 (35.4)3638/10 708 (34.00)Difficulty swallowing†
0.111.21 (0.96 to 1.54)0.061.22 (0.99 to 1.51)111/1888 (5.9)556 /11 435 (4.9)Earache†
0.620.85 (0.44 to 1.63)0.720.88 (0.44 to 1.77)9/1888 (0.5)62/11 434 (0.5)Vomiting†
0.161.33 (0.89 to 1.99)0.031.58 (1.05 to2.36)30/1888 (1.56)116/11 437 (1.0)Abdominal pain†
Examination:
0.031.18 (1.01 to 1.38)0.011.20 (1.05 to 1.37)325/1828 (17.8)1687/11 050 (15.3)Temperature >37.5°C
0.421.06 (0.92 to 1.22)0.911.01 (0.91 to 1.11)648/1891 (34.3)3907/11 448 (34.1)Purulent tonsils
0.281.08 (0.94 to 1.25)0.861.01 (0.90 to 1.13)1340/1801 (74.4)8111/10 930 (74.2)Cervical glands
0.060.89 (0.78 to 1.01)0.080.92 (0.83 to 1.01)748/1883 (39.7)4775/11 411 (41.9)Tender cervical glands
0.441.08 (0.89 to 1.31)0.401.07 (0.92 to 1.23)244/1792 (13.6)1408/10 925 (12.9)Severely inflamed tonsils
0.151.13 (0.96 to 1.34)0.041.15 (1.01 to 1.32)307/1877 (16.4)1650/11 380 (14.5)Fetor
0.741.03 (0.85 to 1.26)0.941.00 (0.89 to 1.12)453/1878 (24.1)2760/11 404 (24.2)Palatal oedema
*Controlling for clustering, antibiotic prescribing and other independently predictive covariates (sex, age, number of medical problems, fever in past 24 hours, high
temperature, and muscle aches).
†Defined as very bad.
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Univariate odds ratio (95%
CI)
No (%) with new or
unresolving symptoms






0.160.91 (0.80 to1.04)0.060.89 (0.79 to1.01)596 (32.4)3873 (34.6)2
0.650.96 (0.82 to1.13)0.090.89 (0.78 to1.02)420 (22.8)2733 (24.4)3
0.011.33 (1.06 to1.66)0.031.22 (1.02 to1.47)173 (9.4)822 (7.3)4
n=1764n=10 772FeverPAIN:
—1.00—1.00926 (52.5)5549 (51.5)0/1
0.530.95 (0.83 to1.10)0.320.94 (0.83 to1.06)431 (24.4)2750 (25.5)2
0.840.98 (0.82 to1.17)0.420.94 (0.81 to1.09)246 (14.00)1570 (14.6)3
0.261.12 (0.92 to1.37)0.481.07 (0.89 to1.28)161 (9.1)903 (8.4)4/5
n=1767n=10 804FeverP(A)IN†:
—1.00—1.001222 (69.2)7481 (69.2)0/1
0.921.01 (0.86 to1.18)0.670.97 (0.85 to1.11)331 (18.7)2084 (19.3)2
0.820.98 (0.81 to1.18)0.690.96 (0.80 to1.15)153 (8.7)972 (9.0)3
0.011.56 (1.10 to2.22)0.021.40 (1.05 to1.86)61 (3.5)267 (2.5)4
*Controlling for clustering and antibiotic prescribing.
†Not including attendance.
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Univariate odds ratio (95%
CI)
No (%) with new or
unresolving symptoms
(n=1897)




0.0481.19 (1.00 to 1.41)0.041.15 (1.01 to 1.31)314 (16.6)1686 (14.7)1
0.761.08 (0.66 to 1.79)0.741.08 (0.68 to 1.70)22 (1.2)126 (1.1)2
*Controlling for clustering and antibiotic prescribing.
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Figure
Patient recruitment and follow-up. *Baseline case report form and notes review as in DESCARTE (Decision rule for the
Symptoms and Complications of Acute Red Throat in Everyday practice) but also throat swab sent for microbiological
diagnostic study. †As in DESCARTE but patients randomised to delayed antibiotics, antibiotics targeted by clinical score,
or antibiotics targeted by clinical score and rapid test for streptococci. 407 children in the PRISM trial were not included in
the analysis of complications. ‡Self completed postcards were used for 87 people with no data on complications in notes
review, and a further 11 people were included in notes review but had no baseline data
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